Nutraceutical Brand Marketing India 2026 — FSSAI + DMRA Boundaries | ICG

Nutraceutical Brand Marketing — FSSAI + DMRA Boundaries

Slug: `/insights/nutraceutical-brand-marketing-fssai-dmra-india` Primary KW: nutraceutical marketing india fssai Meta title: Nutraceutical Brand Marketing India 2026 — FSSAI + DMRA Boundaries | ICG Meta desc: Nutraceutical marketing India 2026. FSSAI claim standards, DMRA prohibited claims, doctor recommendation strategy, prescription-adjacent positioning. ICG playbook. H1: Nutraceutical brand marketing India 2026 — the FSSAI and DMRA boundaries that define what you can say. Author: ICG Editorial (Pharma Practice) Schema: Article + FAQPage Priority: P1 Word count: ~2,000

Key sections:

Section 1: FSSAI's claim hierarchy for nutraceuticals Tier 1 — Nutritional content claims: "Contains 500mg Vitamin C per serving." Permitted without additional substantiation. Tier 2 — Health function claims: "Vitamin C contributes to normal immune system function." Permitted with scientific backing for the ingredient-function relationship. Tier 3 — Reduction of disease risk claims: "High calcium intake may reduce the risk of osteoporosis." Permitted only if FSSAI has specifically approved this claim category for the ingredient. Very limited list. Prohibited — Disease prevention/treatment claims: "Prevents osteoporosis" or "Treats osteoporosis." DMRA Act prohibition.

Section 2: The prescription-adjacent positioning Nutraceuticals that doctors recommend as adjuncts to prescription treatment (omega-3 for cardiovascular support alongside statins, CoQ10 for patients on statins, probiotics alongside antibiotics) have a unique marketing channel: HCP-directed recommendation.

ICG's prescription-adjacent nutraceutical programme: HCP education through UCPMP-adjacent (not strictly UCPMP — nutraceuticals are not drugs) digital engagement, doctor sample programme, medical education content positioning the nutraceutical's role in clinical practice.

Section 3: DMRA Act — the most commonly violated rule DMRA 1954 prohibits claims that a drug or remedy cures, prevents, or mitigates the effects of conditions including: sexual dysfunction, obesity, height increase, hair loss, skin lightening, arthritis, and various organ conditions. Most nutraceutical brand social media content violates DMRA at some point. ICG's DMRA check is applied to all nutraceutical brand content before publication.

5 FAQs: FSSAI vs AYUSH which governs nutraceuticals, doctor recommendation programme for nutraceuticals without UCPMP, DMRA enforcement mechanism, nutraceutical Meta advertising claim standards, international nutraceutical label vs India marketing claim alignment.